Swedish start-up Atrogi has enrolled the first patient in its Phase Ia/b study of ATR-258, a novel b2adrenoceptor agonist for the treatment of type 2 diabetes and comorbidities. Conducted in Mannheim, Germany by Clinical Research Services (CRS), the trial is expected to be completed by April 2023… Read More
Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong takes a look at Lithuania’s life sciences sector and what it means for start-ups operating in the country. A one to watch, would be my first thoughts when thinking about Lithuania and its start-up sector. After… Read More
Myosana Therapeutics has completed a seed funding round totalling over $5 million led by investor John Ballantyne. The capital will go towards developing Myosana’s gene therapy platform for neuromuscular and cardiac disease, with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025. Read More
Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round. The financing was led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, and renowned angel investors… Read More
Listen to this article on the DDW podcast: DDW Multimedia Editor Megan Thomas observes the 2023 drug discovery landscape, speaking to industry experts and looking at the foundations of 2022 on which next year will lean. Virtual clinical trials ‘Virtual’ and ‘technology’ are concepts which are readily… Read More
Tellus Therapeutics, a company developing treatments for newborns in the neonatal intensive care unit (NICU), announced the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund. The capital will be used to continue preclinical work conducted through the seed… Read More
A project creating a new class of therapeutic proteins to modulate cell signalling has been accepted into the BioInnovation Institute (BII) Bio Studio programme. The project is based on recent breakthroughs in artificial intelligence (AI) and protein design, and uses methods pioneered by David Baker’s laboratory at the University of… Read More
Biotechnology company Infinimmune has closed a $12 million seed round to focus on human-derived antibody drugs. The seed funding was led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier. “The industry has proven the value of antibody-based… Read More
Neobe Therapeutics, an early-stage startup, has raised £520K ($628,000) in equity funding to engineer live biotherapeutics to remove barriers to immune infiltration in solid tumours. While immunotherapies have revolutionised the treatment of cancer, the large majority of patients with solid tumours (up to 85%) still do not… Read More
A new biotechnology company plans to pioneer the integrated mapping of disease networks for precision therapeutics. Rezo Therapeutics has launched with $78 million from a Series A financing, led by SR One, a16z Bio + Health, and Norwest Venture Partners. The company’s platform is based on technology from the Quantitative… Read More
ProductLife Group has been chosen as the exclusive Privileged Partner for Regulatory & Compliance services by EIT Health’s Venture Centre of Excellence (VCoE). The partnership means EIT Health will… Read More
DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research. Japan continues to be one of the largest pharmaceutical markets in the world,… Read More
Listen to this article on the DDW podcast: Dr Stephan Emmerth and Paul Eschmann, Basel Area Business & Innovation, explain the benefits of being based in Basel – the talent pool, global players, academic institutions and investors, for example. Companies specialising in oncology R&D… Read More
Lab space provider Pioneer Group has begun work on 20,000 square feet of purpose-built lab space at the company’s Edinburgh Technopole campus. Branded Moubray, the new building will cater to all segments of the market – from start-ups to blue-chip companies – and is expected to be finished… Read More
Listen to this article on the DDW podcast: DDW Editor, Reece Armstrong, sits down with Brinter CEO Tomi Kalpio to learn about the company’s approach to bioprinting and how it can be used throughout drug discovery. Brinter is a provider of 3D… Read More
A female-led start-up developing a live biotherapeutic product to address infant gut needs, has raised £1.3M ($1.5M) in equity and grant funding. BoobyBiome, founded by scientists Dr Lydia Mapstone, Dr Sioned Jones and Tara O’Driscoll, aims to develop a novel product for babies who do not have access to… Read More
